GSK Bio

GlaxoSmithKline plc and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion).

GlaxoSmithKline announced it will acquire the Tesaro, based in Waltham, Mass., for $5.1 billion. For GSK, the deal marks an increased focus on oncology as it focuses on high growth areas.

Rheostat Therapeutics today announced the close of a Series A financing round totaling $23 million.

Exscientia, the company leading the use of Artificial Intelligence (AI) in drug discovery, announces that is has acquired the biophysics specialists, Kinetic Discovery, a private UK company. The acquisition builds up Exscientia’s capabilities for tackling novel drug targets to create first-in-class drug candidates by seeding its algorithms with data generated through the use of fragment screening and structural biology.

Sareum Holdings plc is pleased to announce the appointments of Michael Owen, PhD and Clive Birch as Non-Executive Directors.

Consilium Strategic Communications today announces the appointment of Alex Harrison as a Senior Advisor.

YUPELRI (revefenacin) is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US

The number of life science jobs grew by 12,500 for an approximate total of a total estimated employment of 311,226. That was music to the ears of Sara Radcliffe, president and chief executive officer of the California Life Sciences Association.

This deal is an expansion of an existing discovery collaboration. Immunocore will head the first-in-human clinical trial of the drug alone and in combination with Genentech’s checkpoint inhibitor Tecentriq (atezolizumab).